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AbstrAct
Objective In the era of limited healthcare budgets, 
healthcare costs of heart valve implantations need to be 
considered to inform cost-effectiveness analyses. We 
aimed to provide age group-specific costs estimates of 
heart valve implantations, related complications and other 
healthcare utilisation following the intervention.
Methods We performed retrospective analyses of 
healthcare costs of patients who had undergone heart 
valve implantations in 2010–2013 and controls using 
claims data from Dutch health insurers. Heart valve 
implantations included surgical valve replacement 
and transcatheter valve implantation in all heart valve 
positions. Patients were divided in four age groups. Control 
groups were created by taking random samples of the 
Dutch population stratified by age, gender, socioeconomic 
status and comorbidities. We applied non-parametric 
bootstrapping to address uncertainty of the cost estimates. 
The association of patient and intervention characteristics 
with costs was determined by (multilevel) generalised 
linear models.
Results The baseline characteristics of 18 903 patients 
and 188 925 controls were comparable. The annual 
healthcare costs were substantially higher for surgical 
heart valve replacement patients than for controls, 
especially in the year of heart valve implantation. Factors 
associated with increased annual healthcare costs for 
patients were older age, female gender, comorbidities, low 
socioeconomic status and complications.
Conclusions We provided a comprehensive overview 
of age group-specific incidence of heart valve 
implantations, subsequent survival and complications 
as well as associated healthcare costs of all patients in 
the Netherlands. Our results provide real-world costs 
estimates that can be used as a benchmark for costs of 
future innovative heart valve implantations.
IntROduCtIOn
Heart valve disease has a profound impact 
on the use and costs of healthcare. This 
impact is even greater for heart valve disease 
than for coronary heart disease, despite the 
higher prevalence of coronary heart disease.1 
In developed countries, the prevalence of 
heart valve disease is 2.5%, and this prev-
alence is the highest in patients aged ≥75 
years (13.3%).2 Due to an ageing population, 
Key questions
What is already known about this subject?
 ► Due to the ageing of the population, the number 
of patients with heart valve disease is expected 
to increase as is the number of heart valve 
replacements. The scarcity of resources for 
healthcare requires an analysis of the impact of 
this development on costs and cost-effective 
ness.
 ► Comprehensive and comparable cost estimates for 
the entire target population and its subgroups are 
lacking. The costs of surgical valve replacement 
and transcatheter valve implantation and 
subsequent healthcare use have only been 
estimated for specific risk groups such as elderly 
high or intermediate surgical risk patients. 
Moreover, these estimates include only short-term 
costs.
What does this study add?
 ► This study adds valuable real-world, age group-
specific cost estimates of all costs associated with 
heart valve implantations (in all valve positions), 
including the costs of heart valve implantations 
itself, complications and healthcare use in the 
years following the heart valve implantation. 
Furthermore, this study provides a unique insight 
in the differences in incidence, health outcomes 
and (predictors of the) associated healthcare costs 
of heart valve implantations between patients with 
different ages.
How might this impact on clinical practice?
 ► Cost-effectiveness is increasingly becoming 
an important hurdle for introduction of new 
interventions in clinical practice. Our results 
can be used as a benchmark for the costs of 
new technologies in the field of heart valve 
implantations that will be introduced in clinical 
practice in the future, such as tissue-engineered 
heart valves. To estimate the cost-effectiveness, 
healthcare decision makers need information 
about the cost-effectiveness in the real world. Our 
results provide valuable input for the costs in cost-
effectiveness analyses of heart valve implantations 
based on data generated in routine care instead of 
under experimental conditions.
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the number of patients with heart valve disease requiring 
valve replacement is expected to rise, reaching more 
than 800 000 annual procedures worldwide by 2050.3 As 
a result, healthcare expenditures and societal burden of 
heart valve disease will increase.
In patients with severe heart valve disease, replacement 
of the native valve with a heart valve substitute may be 
required. There are different effective options, but every 
heart valve substitute type also has its limitations.4 In the 
future, these limitations may be reduced with the many 
emerging technologies in the field of heart valve inter-
ventions, such as tissue-engineered heart valves and less 
invasive implantation methods. Before these new technol-
ogies can be introduced in clinical practice, it is important 
to establish that they are effective and cost-effective, 
considering the scarcity of resources for healthcare. To 
determine whether a new intervention is cost-effective, 
the costs and effects of the new intervention need to be 
compared with current care. Since the choice of heart 
valve implantation and its outcomes differs substantially 
among age groups,5 it is likely that healthcare costs will 
also be influenced by patients’ age. Hence, having robust 
age group-specific estimates of the costs of current care 
is important.
The objective of this study was to estimate the costs of 
currently used heart valve implantations and also costs of 
complications as well as healthcare use outside hospitals 
in the years after heart valve implantations in different 
age groups. We estimated these costs by retrospective 
analyses of health insurance claims of patients who had 
undergone heart valve implantations. This provides 
valuable real-world age group-specific cost estimates 
of all costs associated with heart valve implantations, in 
comparison with previous studies that focused on costs of 
the heart valve implantation and short-term follow-up in 
specific age groups only.6 7
MetHOds
Patients
We used health insurance claims databases (‘Vektis’) that 
contain the healthcare expenditures of all the insured 
in the Netherlands, which is 99% of all Dutch residents 
(±17 million people). Patients were selected using Diag-
nosis Related Group (DRG) codes of heart valve implan-
tations (online supplementary table S1). We could distin-
guish DRG codes for isolated or multiple surgical heart 
valve replacement (SVR) and transcatheter heart valve 
implantation (TVI) in every heart valve position with 
or without concomitant procedures. In the pulmonary 
and tricuspid valve position, DRG codes did not distin-
guish between valve repair and replacement; therefore, 
patients who have undergone repairs in these valve posi-
tions are also included in our patient population.
We used data from Vektis for the years 2010–2013. Data 
before 2010 are generally considered less valid. On the 
date of data extraction for this study (January 2016), data 
from the years 2014 and further were incomplete due 
to time lags in administrations. Before 2013, there was 
no specific DRG code for TVI; therefore, we could only 
include TVI patients in the year 2013.
Controls
To calculate the excess healthcare costs due to the heart 
valve implantation, we compared annual healthcare 
costs of the patient group with a control group. The 
control group was created by stratified sampling from 
the remainder of the Dutch insured population in the 
Vektis databases to ensure that the distributions of person 
characteristics across the strata were similar to that in the 
patient population. The control group was 10 times as 
large as the patient population. Strata were based on age 
class, gender, socioeconomic status (SES) and comor-
bidities. Age was divided into nine age classes: 0–1, 2–18, 
19–30, 31–40, 41–50, 51–60, 61–70, 71–80 and >80 years. 
SES was based on status scores reflecting the SES of a 
district based on characteristics of its residents: education, 
income and position on the labour market.8 The status 
scores were divided in four groups based on percentiles, 
with lower percentiles representing lower SES. Comor-
bidities were based on Pharmacy Cost Groups, which 
is an outpatient morbidity measure based on prior use 
of prescribed drugs as marker for chronic conditions.9 
The strata used for comorbidities differed per age class 
because of differences in prevalence of comorbidities 
(see online supplement).
Healthcare costs
Patients were followed over time from the opening date of 
the heart valve implantation DRG in the financial admin-
istrative system until death or until 31 December 2013, 
whichever occurred first, to assess whether they experi-
enced complications after the heart valve implantation 
and to collect their other healthcare costs besides the 
costs of heart valve implantation itself.
For every patient, the costs of the initial heart valve 
implantation and the healthcare costs during the first 
postintervention year and subsequent (max. 4) years were 
determined. Costs were defined as expenditures reim-
bursed by health insurers and expressed in euros (€). 
The procedure costs included the costs of the DRG and 
intensive care unit (ICU) stay. We assumed that the costs 
of ICU stay in the first postintervention year excluding 
the ICU costs related to specific complications were 
related to the heart valve implantation.
Complications were extracted from the Vektis data-
base using DRG codes for treatment of complications 
(online supplementary table S2). The complications of 
interest were based on the conceptual model we have 
developed previously.5 The following complications were 
available in the Vektis database: acute kidney injury, 
atrial fibrillation (AF), stroke, transient ischaemic attack, 
prosthetic valve endocarditis (conservative treatment), 
myocardial infarction, pacemaker implantation and rein-
tervention (redo heart valve implantation). For every 
complication, costs (DRG+ICU costs), proportions of 
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Valvular heart disease
patients admitted to the ICU and number of ICU days 
were determined.
For both patients and controls, annual healthcare costs 
were determined. The starting point of the calculation of 
annual healthcare costs of patients is the quarter in which 
the heart valve implantation was performed. The annual 
healthcare costs were classified into costs of general 
practitioners, specialised medical care (both inpatient 
and outpatient care, including costs of DRGs, ICU stay, 
medicines on the expensive drugs list, primary care diag-
nostics and other costs), pharmaceuticals, paramedical 
care, patient transport, home care, nursing homes and 
geriatric rehabilitation care. Cost of medicines on the 
expensive drug list, home care, nursing homes and geri-
atric rehabilitation care were only available in the Vektis 
database from the year 2012 onwards.
statistical analysis
The statistical analyses were performed with SAS V.9.4 
using SAS Enterprise Guide V.7.1.
Descriptive analyses
Patients and controls were divided in four age groups: chil-
dren (0–18 years), young adults (19–60 years), middle aged 
(61–70 years) and elderly patients (>70 years). For every 
age group, we performed descriptive analyses of person and 
intervention characteristics, occurrence of complications 
and healthcare costs. Continuous variables were depicted 
as means and standard deviation (SD) or 95% confidence 
interval (CI) and discrete variables as counts and propor-
tions. We assessed survival after SVR and TVI using Kaplan-
Meier estimates. The difference between mean healthcare 
costs of patients and controls was calculated; mean costs of 
controls were based on the same calendar years as patients 
(eg, for patients postintervention year 2 could be between 
2011 and 2013; therefore, these costs were compared 
with the average costs of controls in 2011–2013). As the 
cost data were skewed, non-parametric bootstrapping 
(2000 replications) was used to address uncertainty (with 
95% CI based on 2.5th and 97.5th percentile) in the annual 
healthcare costs. To be able to report annual healthcare 
costs, only patients who were followed the entire year of 
interest (including patients who died during this year) were 
included in these analyses.
Association analyses
To estimate the association between healthcare costs and 
patient and intervention characteristics, we developed 
(multilevel) generalised linear models ((M)GLM) for 
intervention, complication and annual healthcare costs. 
For annual healthcare costs of patients after heart valve 
implantations, we estimated a MGLM for children and 
for adults with normal distributions and identity links and 
with several observation periods per patient. All patients 
with at least 1-year complete follow-up were included. We 
excluded patients with incomplete follow-up in the first 
post intervention year (except for patients who died) to 
avoid overestimation of costs per day in post intervention 
year one due to the high costs in the period after the 
intervention. To correct for differences in total dura-
tion of follow-up, the total healthcare costs were divided 
by the follow-up duration to estimate average costs per 
day during the specific year. The independent varia-
bles included in the MGLMs for children and adults 
were time (ie, intervention period (no defined length; 
includes costs of heart valve implantation and ICU stay), 
remaining postintervention year 1 and postintervention 
years 2, 3 and 4), gender and SES. In addition, the model 
of adults included age groups, comorbidities, mortality 
and complications. Mortality and the occurrence of 
complications were time dependent. Comorbidities, 
mortality and the occurrence of complications were not 
included in the model for children because there were no 
children with comorbidities and only a small proportion 
of children who experienced complications (including 
mortality). Details about the GLMs in which the costs of 
interventions and complications were analysed separately 
can be found in the online supplementary material.
Results
study population
In total, we included 18 903 patients (SVR: n=17 991, TVI: 
n=912) and 188 925 controls. The baseline characteris-
tics of patients and controls were comparable (table 1). 
The mean (median) follow-up was 1.9 (1.9) and 0.4 (0.4) 
years for SVR and TVI patients, respectively. Figure 1 
illustrates the Kaplan-Meier survival curves after SVR and 
TVI. During follow-up, 41 children (10.0%), 841 young 
adults (26.2%), 1424 middle-aged patients (29.5%) 
and 3036 elderly patients (31.9%) experienced one 
or more complications after SVR. After TVI, six young 
adults (18.2%), two middle aged (2.9%) and 157 elderly 
patients (19.4%) experienced complications.
Table 2 presents the occurrence of complications per 
postintervention year, the proportion of patients with ICU 
stay and the mean length of ICU stay after complications.
Healthcare costs: descriptive analyses
Table 3 and figure 2 summarise the costs of heart valve 
implantations, complications and total annual healthcare 
costs during the first three postintervention years divided 
by age group. These costs could not be determined for 
TVI patients because their follow-up was less than 1 year. 
The annual healthcare costs of patients were substantially 
higher than the costs of controls in all age groups, especially 
in the year of implantation (figure 2; children €11 766 vs 
€796, young adults €15 060 vs €2944, middle aged €16 104 
vs €4612 and elderly €18 255 vs €9236). The patients’ 
annual healthcare costs were substantially higher than 
controls for most types of healthcare across all age groups 
(online supplementary tables S3–S6). However, middle-
aged and elderly patients had substantially lower costs 
of nursing homes than controls in postintervention year 
1 (€866 vs €2761). The costs of nursing homes remained 
substantially lower in elderly patients in postintervention 
 o
n
 18 Decem
ber 2018 by guest. Protected by copyright.
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2017-000672 on 14 February 2018. Downloaded from
 
Open Heart
4 Huygens SA, et al. Open Heart 2018;5:e000672. doi:10.1136/openhrt-2017-000672
Ta
b
le
 1
 
P
er
so
n 
an
d
 in
te
rv
en
tio
n 
ch
ar
ac
te
ris
tic
s 
of
 p
at
ie
nt
s 
an
d
 c
on
tr
ol
s 
d
iv
id
ed
 b
y 
ag
e 
gr
ou
p
C
hi
ld
re
n 
(0
–1
8 
ye
ar
s)
Yo
un
g
 a
d
ul
ts
 (1
9–
60
 y
ea
rs
)
M
id
d
le
 a
g
ed
 (6
1–
70
 y
ea
rs
)
E
ld
er
ly
 (>
70
 y
ea
rs
)
P
at
ie
nt
s
C
o
nt
ro
ls
P
at
ie
nt
s
C
o
nt
ro
ls
P
at
ie
nt
s
C
o
nt
ro
ls
P
at
ie
nt
s
C
o
nt
ro
ls
S
V
R
S
V
R
T
V
I
S
V
R
T
V
I
S
V
R
T
V
I
N
um
b
er
 o
f 
p
er
so
ns
,*
 n
 (%
)
41
1
41
70
32
13
 (9
9.
0)
33
 (1
.0
)
33
 9
60
48
26
 (9
8.
6)
70
 (1
.4
)
50
 4
40
95
27
 (9
2.
2)
80
9 
(7
.8
)
10
,0
35
5
Fo
llo
w
-u
p
 in
 y
ea
rs
,†
 m
ea
n±
SD
2.
2±
1.
2
<
4.
0
2.
0±
1.
2
0.
5±
0.
3
<
4.
0
1.
9±
1.
2
0.
4±
0.
3
<
4.
0
1.
8±
1.
2
0.
4±
0.
3
<
4.
0
A
g
e 
at
 t
im
e 
o
f 
in
te
rv
en
ti
o
n,
 
m
ea
n±
SD
, r
an
ge
5.
5±
6.
2
–
50
.3
±
9.
4
39
.4
±
14
.9
– 
66
.0
±
2.
8
66
.9
±
2.
1
–
77
.6
±
4.
4
81
.9
±
4.
9
–
0–
18
0–
18
19
–6
0
19
–6
0
19
–6
0
61
–7
0
62
–7
0
61
–7
0
71
–9
4
71
–9
5
>
70
M
al
e,
 n
 (%
)
24
5 
(5
9.
6)
24
90
 (5
9.
7)
21
40
 (6
6.
6)
23
 (6
9.
7)
22
 7
30
 (6
6.
9)
32
61
 (6
7.
6)
43
 (6
1.
4)
33
 7
70
 (6
7.
0)
50
75
 (5
3.
3)
38
7 
(4
7.
8)
47
 5
80
 (4
7.
4)
S
E
S
,‡
 n
 (%
)
 
   0–
20
72
 (1
7.
5)
72
0 
(1
7.
3)
73
7 
(2
2.
9)
4 
(1
2.
1)
76
50
 (2
2.
5)
98
7 
(2
0.
5)
23
 (3
2.
9)
10
 5
30
 (2
0.
9)
20
42
 (2
1.
4)
20
2 
(2
5.
0)
21
 7
80
 (2
1.
7)
 
   21
–4
0
80
 (1
9.
5)
81
0 
(1
9.
4)
68
1 
(2
1.
2)
6 
(1
8.
2)
72
50
 (2
1.
3)
99
4 
(2
0.
6)
12
 (1
7.
1)
10
 3
10
 (2
0.
4)
20
31
 (2
1.
3)
16
1 
(1
9.
9)
21
 2
80
 (2
1.
2)
 
   41
–7
0
12
4 
(3
0.
2)
12
50
 (3
0.
0)
89
7 
(2
7.
9)
11
 (3
3.
3)
95
70
 (2
8.
2)
15
87
 (3
2.
9)
16
 (2
2.
9)
16
 4
90
 (3
2.
7)
29
84
 (3
1.
3)
22
8 
(2
8.
2)
31
 1
80
 (3
1.
1)
 
   71
–1
00
13
5 
(3
2.
8)
13
90
 (3
3.
3)
88
8 
(2
7.
6)
12
 (3
6.
4)
93
80
 (2
7.
6)
12
56
 (2
6.
0)
19
 (2
7.
1)
13
 0
90
 (2
6.
0)
24
69
 (2
5.
9)
21
8 
(2
6.
9)
26
 1
10
 (2
6.
0)
C
o
m
o
rb
id
it
ie
s,
 n
 (%
)
 
   CO
PD
,  D
M
, k
id
ne
y 
di
se
as
e 
an
d/
or
 H
F
78
0 
(2
4.
3)
9 
(2
7.
3)
85
10
 (2
5.
1)
20
86
 (4
3.
2)
47
 (6
7.
1)
22
 1
60
 (4
3.
9)
50
41
 (5
2.
9)
51
8 
(6
4.
0)
54
 1
45
 (5
4.
0)
 
   Hy
pe
rte
ns
io
n
11
06
 (3
4.
4)
6 
(1
8.
2)
11
 6
00
 (3
4.
2)
16
59
 (3
4.
4)
17
 (2
4.
3)
17
 3
30
 (3
4.
4)
30
36
 (3
1.
9)
19
9 
(2
4.
6)
31
 3
10
 (3
1.
2)
 
   Ot
he
r c
om
or
bi
di
tie
s
29
3 
(9
.1
)
3 
(9
.1
)
31
70
 (9
.3
)
41
6 
(8
.6
)
3 
(4
.3
)
42
10
 (8
.3
)
57
5 
(6
.0
)
36
 (4
.4
)
58
80
 (5
.9
)
 
   No
 c
om
or
bi
di
tie
s
41
1 
(1
00
.0
)
41
70
 (1
00
.0
)
10
34
 (3
2.
2)
15
 (4
5.
5)
10
 6
80
 (3
1.
4)
66
5 
(1
3.
8)
3 
(4
.3
)
67
40
 (1
3.
4)
87
5 
(9
.2
)
56
 (6
.9
)
90
20
 (9
.0
)
Va
lv
e 
p
o
si
ti
o
n,
 n
 (%
)
 
   Ao
rti
c
29
 (7
.1
)
24
60
 (7
6.
6)
6 
(1
8.
2)
41
33
 (8
5.
6)
25
 (3
5.
7)
85
78
 (9
0.
0)
39
5 
(4
8.
8)
 
   Pu
lm
on
ar
y
33
8 
(8
2.
2)
11
5 
(3
.6
)
2 
(0
.0
)
2 
(0
.0
)
 
   M
itr
al
19
 (4
.6
)
43
1 
(1
3.
4)
2 
(6
.1
)
48
4 
(1
0.
0)
1 
(1
.4
)
65
2 
(6
.8
)
 
   Tr
ic
us
pi
d
23
 (5
.6
)
65
 (2
.0
)
34
 (0
.7
)
36
 (0
.4
)
 
   Ao
rti
c 
an
d 
m
itr
al
2 
(0
.5
)
14
2 
(4
.4
)
17
3 
(3
.6
)
25
9 
(2
.7
)
 
   Un
kn
ow
n
25
 (7
5.
8)
44
 (6
2.
9)
41
4 
(5
1.
2)
C
o
nc
o
m
it
an
t 
p
ro
ce
d
ur
es
, n
 (%
)
 
   No
 c
on
co
m
ita
nt
 p
ro
ce
du
re
s
21
4 
(5
2.
1)
19
24
 (5
9.
9)
33
 (1
00
.0
)
24
85
 (5
1.
5)
70
 (1
00
.0
)
47
35
 (4
9.
7)
80
7 
(9
9.
8)
 
   CA
BG
40
7 
(1
2.
7)
13
64
 (2
8.
3)
34
09
 (3
5.
8)
2 
(0
.2
)
 
   Va
lv
e 
re
pa
ir
1 
(0
.2
)
25
3 
(7
.9
)
34
4 
(7
.1
)
64
3 
(6
.7
)
 
   M
az
e+
CA
BG
 or
 v
al
ve
 re
pa
ir
58
 (1
.8
)
21
2 
(4
.4
)
41
8 
(4
.4
)
 
   Be
nt
al
l
8 
(1
.9
)
30
3 
(9
.4
)
16
2 
(3
.4
)
94
 (1
.0
)
 
   Ao
rti
c 
as
ce
nd
en
s
17
3 
(5
.4
)
16
1 
(3
.3
)
11
4 
(1
.2
)
 
   Te
tra
lo
gy
 o
f F
al
lo
t
18
7 
(4
5.
5)
6 
(0
.2
)
 
   Ao
rti
c 
as
ce
nd
en
s+
va
lv
e 
re
pa
ir
27
 (0
.8
)
31
 (0
.6
)
36
 (0
.4
)
 
   HO
CM
11
 (0
.3
)
14
 (0
.3
)
52
 (0
.5
)
Co
nt
in
ue
d
 o
n
 18 Decem
ber 2018 by guest. Protected by copyright.
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2017-000672 on 14 February 2018. Downloaded from
 
5Huygens SA, et al. Open Heart 2018;5:e000672. doi:10.1136/openhrt-2017-000672
Valvular heart disease
years 2 and 3 (€1763 (year 2) and €1990 (year 3) vs €2761 
for controls). In addition, costs of home care were lower 
for elderly patients than controls in the first year after the 
intervention(€1199 vs €1330).
Healthcare costs: association analyses
Table 4 presents the results of the MGLMs of annual 
healthcare costs for children and adult SVR patients. 
Annual healthcare costs for adult SVR patients increased 
with older age at intervention (on average+€2441 
for elderly vs middle aged patients), comorbidities 
(on average+€6543 for patients with chronic obstruc-
tive pulmonary disease, diabetes mellitus, kidney disease 
and/or HF vs patients without comorbidities) and lower 
SES (on average+€1160 for patients with lowest vs highest 
SES). Men had somewhat lower costs than women (€1110 
on average). If patients experience a complication, their 
annual healthcare costs increase on average with €623 
after AF to €30 094 after reintervention. If patients die, 
their costs in the year of death increase on average with 
€6106. For children, costs were not associated with 
gender or SES. The results of the GLMs for intervention 
and complication costs are reported in online supple-
mentary tables S7 and S8.
dIsCussIOn
Using the comprehensive Vektis databases, we were able 
to estimate the real-world age group-specific incidence 
of heart valve implantations, subsequent survival and 
complications as well as the associated healthcare costs 
of all patients in the Netherlands who had undergone 
a heart valve implantation during our study period. 
Although the estimates are specific to the Dutch health-
care system, the results regarding differences between 
age groups, distribution of costs over types of health-
care and associations between patient and intervention 
characteristics and healthcare costs are also relevant for 
other countries. Our results can help raise awareness of 
the costs associated with heart valve implantations among 
clinicians and healthcare policy makers, which is impor-
tant in the current era of limited healthcare budgets. 
However, we want to emphasise that considerations about 
costs should not play a role in the treatment decision for 
individual patients. Instead the results can be used as a 
benchmark in cost-effectiveness analyses for new technol-
ogies that will be introduced in clinical practice in the 
future, such as tissue-engineered heart valves.5
This study has shown that Dutch health insurers spent 
over €120 million per year on procedure costs for heart 
valve implantations, of which 2% is spent on children, 
17% on young adults, 26% on middle aged and 56% on 
elderly patients. Although there were no substantial differ-
ences in procedure costs between age groups, the costs of 
SVR were generally higher in older patients, while costs of 
TVI were lower for older patients. There was no trend in 
complication costs in relation to age groups. In addition 
to procedure costs, patients had excess healthcare costs 
C
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after the heart valve implantation compared with controls 
in almost all types of healthcare. These excess healthcare 
costs were especially high in the year of heart valve implan-
tation; 41 (children), 14 (young adults), 9 (middle aged) 
and 5 (elderly) fold higher in patients than controls. In 
the subsequent postintervention years, however, the excess 
healthcare costs decreased. This decrease may be explained 
by survival of the fittest patients.
In contrast to other types of healthcare, the costs 
of nursing homes were substantially lower for elderly 
patients than for controls. This may be caused by selec-
tion bias of relatively healthy elderly patients for SVR. 
Patients living in nursing homes may be less likely to 
undergo heart valve implantation due to other factors 
influencing someone’s health state, such as frailty or 
dementia. Since these factors could not be taken into 
account when defining the control sample, people living 
in nursing homes may be over-represented in the control 
group as compared with the patient group.
As expected, older age, female gender, comorbidities, 
low SES and/or experiencing complications (including 
death) were associated with higher annual healthcare 
costs. It should be noted that the aim of this study was 
to describe and predict costs and that it does not make 
casual claims. Nevertheless, some explanations for the 
associations can be considered. The association of lower 
SES and poor health has also been shown consistently 
in previous research.10 The association of gender and 
Figure 1 Kaplan-Meier curves of survival after SVR (top) and TVI (bottom) divided by age group. SVR, surgical heart valve 
replacement; TVI, transcatheter heart valve implantation.
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Valvular heart disease
costs, even after adjusting for comorbidities and compli-
cations, is in line with previous research that found that 
women have higher healthcare costs than men.11 In 
cardiovascular diseases, this might be due to the different 
preoperative risks profiles of women compared with 
men,12 13 which may be caused by delayed presentation 
or diagnosis of valve problems and/or later referral to 
cardiothoracic surgery of women.12 If these different risk 
Table 3 Costs of initial heart valve intervention and complications
Children (0–18 years) Young adults (19–60 years) Middle aged (61–70 years) Elderly (>70 years)
n Costs (€, mean, CI) n Costs (€, mean, CI) n Costs (€, mean, CI) n Costs (€, mean, CI)
Intervention (including ICU*)
  SVR (total) 399 21 941 (20 543 to 23 811) 3172 25 050 (24 446 to 25 711) 4727 25 502 (25 054 to 25 988) 9387 25 740 (25 414 to 26 058)
  Aortic 29 20 068 (18 843 to 21 279) 2428 23 935 (23 350 to 24 592) 4050 24 553 (24 131 to 25 004) 8448 25 165 (24 845 to 25 482)
  Pulmonary 328 21 800 (20 144 to 23 978) 114 19 442 (18 598 to 20 297) 2 14 483 (11 966 to 17 009) 2 23 702 (21 923 to 25 518)
  Mitral 17 26 885 (19 920 to 35 138) 427 27 449 (25 691 to 29 491) 475 28 493 (26 779 to 30 386) 646 29 408 (27 634 to 31 510)
  Tricuspid 23 22 409 (19 226 to 27 671) 64 33 306 (26 339 to 41 758) 32 26 858 (21 833 to 33 760) 35 23 611 (21 577 to 25 923)
  Aortic+mitral 2 25 451 (20 148 to 30 753) 194 37 985 (32 581 to 44 947) 167 39 834 (34 892 to 45 874) 256 35 759 (33 074 to 38 668)
  TVI (total) 0 – 29 33 385 (30 842 to 36 490) 64 32 440 (30 860 to 34 142) 744 32 209 (31 582 to 32 883)
  Aortic 0 – 6 35 884 (30 552 to 43 785) 21 33 135 (29 843 to 36 786) 366 32 776 (31 812 to 33 842)
  Mitral 0 – 2 33 838 (22 789 to 44 831) 1 36 661 (36 661 to 36 661) 0 –
  Unknown 0 – 21 32 614 (30 134 to 36 300) 42 32 003 (30 193 to 33 909) 378 31 660 (30 915 to 32 563)
Complications (including ICU)
  Acute kidney 
  injury
2 6007 (2617 to 9407) 36 9061 (5575 to 13 552) 81 8021 (6303 to 9988) 169 9533 (7597 to 11 769)
  Atrial fibrillation 11 2702 (717 to 5789) 548 1418 (1295 to 1543) 1087 1229 (1147 to 1313) 2187 1210 (1119 to 1321)
  Stroke 1 1418 (1418 to 1418) 257 3264 (2458 to 4197) 403 2627 (2222 to 3129) 1115 3017 (2731 to 3341)
  TIA 0 – 104 1213 (990 to 1470) 220 1311 (1122 to 1522) 387 1267 (1155 to 1394)
  Endocarditis 6 7971 (3764 to 13 057) 254 7418 (6449 to 8401) 292 7543 (6689 to 8380) 380 8815 (7960 to 9722)
  Myocardial infarction 0 – 49 6248 (4264 to 9517) 83 5421 (4524 to 6518) 203 5094 (4509 to 5911)
  Pacemaker 
  implantation
4 4884 (2175 to 6621) 118 10 987 (10 403 to 11 525) 209 12 395 (10 875 to 15 179) 619 11 596 (11 348 to 11 853)
  Reintervention 22 20 057 (18 326 to 21 784) 70 25 328 (21 590 to 30 273) 72 21 340 (19 249 to 24 120) 135 25 622 (23 138 to 28 862)
*ICU costs during first year minus ICU costs after complications. Only patients with ≥30-days’ follow-up or died ≤30 days included to ensure all ICU costs after 
intervention were considered.
ICU, intensive care unit; SVR, surgical heart valve replacement; TIA, transient ischaemic attack; TVI, transcatheter heart valve implantation. 
Figure 2 Annual healthcare costs during the first three postintervention years of surgical valve replacement patients and 
controls divided by age group.
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profiles result in slower or impaired recovery of women 
compared with men, this might result in more use of 
healthcare and thereby higher annual healthcare costs.
strengths and limitations
An important strength of our study is the use of databases 
including the health insurance claims of 99% of Dutch 
residents. Therefore, almost all patients that have under-
gone heart valve implantations during our study period 
were included, and we presented outcomes in a diverse 
study population that reflects the range and distribution 
of patients in clinical practice instead of focusing on 
specific age or risk groups.14 This resulted in comprehen-
sive analyses of the real-world healthcare costs associated 
with heart valve implantations with high external validity 
and generalisability. Since healthcare decision makers 
need information about the cost-effectiveness in the 
Table 4 Multilevel generalised linear model of total annual healthcare costs after SVR in postintervention years 1–4
Total costs
Children
(0–18 years, n=325)
Adults
(>18 years, n=13 944)
Parameter β 95% CI P value β 95% CI P value
Intercept 16 931 −36 190 to 70 051 0.533 11 338 9906 to 12 770 <0.0001
Time (compared with year 1 excluding 
intervention costs)
  Intervention period* 21 841 20 857 to 22 825 <0.0001 25 492 25 248 to 25 736 <0.0001
  Year 2 −11 519 −67 302 to 44 264 0.686 −2904 −3779 to −2030 <0.0001
  Year 3 −14 952 −67 272 to 37 368 0.576 −1862 −3421 to −302 0.019
  Year 4 −6170 −64 405 to 52 065 0.836 396 −1627 to 2420 0.701
Death 6106 4784 to 7428 <0.0001
Age (compared with elderly)
  Children (0–18 years)
  Young adults (19–60 years) −1179 −2290 to −68 0.038
  Middle aged (61–70 years) −2441 −3359 to −1524 <0.0001
Male 1133 −30 369 to 32 635 0.944 −1110 −1911 to −310 0.007
Comorbidity
(compared with no comorbidity)
COPD, DM, kidney disease and/or HF 6543 5328 to 7757 <0.0001
Hypertension 1309 67 to 2550 0.039
Other comorbidities 1990 218 to 3761 0.028
SES†(compared with highest SES:  
71–100)
  SES 0–20 8553 −36 202 to 53 308 0.708 1160 34 to 2285 0.044
  SES 21–40 2878 −41 065 to 46 821 0.898 301 −823 to 1426 0.599
  SES 41–70 2505 −37 038 to 42 048 0.901 887 −128 to 1901 0.087
Complications
  Atrial fibrillation 2985 1673 to 4296 <0.0001
  Acute kidney inury 19 639 16 611 to 22 667 <0.0001
  Stroke 7755 6181 to 9329 <0.0001
  TIA 623 −2157 to 3403 0.661
  Endocarditis 21 572 18 999 to 24 144 <0.0001
  Myocardial infarction 13 192 9291 to 17 092 <0.0001
  Pacemaker implantation 15 947 13 816 to 18 079 <0.0001
  Reintervention 30 094 25 455 to 34 733 <0.0001
NB: 3622 SVR and all TVI patients were excluded because follow-up <1 year.
*Includes costs of heart valve implantation and ICU stay but no other costs of the first postintervention year (these are included in the 
reference group of this variable).
†Higher percentiles represent higher SES.
 COPD, chronic Obstructive Pulmonary Disease; DM, diabetes mellitus; HF, heart failure; ICU, intensive care unit; SES, socioeconomic status; 
SVR, surgical heart valve replacement; TIA, transient ischaemic attack.
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Valvular heart disease
real world, our results provide valuable input for the costs 
in cost-effectiveness analyses based on data generated in 
routine care instead of under experimental conditions.14 
Furthermore, this study provided a unique insight in the 
differences in incidence, health outcomes and associated 
healthcare costs of heart valve implantations of patients 
with all ages, divided over four informative age groups.
Our study also has some limitations. First, we could not 
separate our results for different types of valve prostheses 
(eg, mechanical and biological prostheses). However, 
although the type of prosthesis has impact on survival and 
complication rates, we do not expect that the type of pros-
thesis has a large impact on healthcare costs. Furthermore, 
since the DRG code for TVI was only available from 2013, 
the follow-up was too short to estimate annual healthcare 
costs in postintervention years for these patients. Addition-
ally, since complications were identified using DRG codes, 
we could only determine the incidence and costs of compli-
cations for which patients were treated in the hospital 
(including outpatient treatment). Furthermore, not all 
inhospital complications could be identified because for 
some complications the costs may be included in the DRG 
of the initial heart valve implantation instead of a separate 
DRG. In addition, the exact date of the heart valve implan-
tation was unknown; instead, the opening date of the DRG 
in the financial administrative system was used as a proxy. 
It is possible that the heart valve implantation took place 
a few days/weeks before or after the opening date of the 
DRG. Furthermore, we could not calculate annual health-
care costs from the exact date of the intervention onwards 
but only from the quarter in which the intervention took 
place. Finally, the reported costs are expenditures reim-
bursed by health insurers based on agreements between 
healthcare providers and insurers, not actual costs.
COnClusIOn
This study provided a comprehensive overview of age 
group-specific incidence of heart valve implantations, 
subsequent survival and complications as well as the asso-
ciated healthcare costs of all patients who had under-
gone a heart valve implantation in the Netherlands. We 
have shown that after heart valve implantation, patients 
have substantially higher healthcare costs than controls. 
The costs are higher in patients with comorbidities and 
patients who have experienced a complication. The 
costs estimated in this study can be used as a benchmark 
for future innovative heart valve implantations, such as 
tissue-engineered heart valves.
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